These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
792 related items for PubMed ID: 8761540
21. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Hutchison AJ, Freemont AJ, Boulton HF, Gokal R. Nephrol Dial Transplant; 1992; 7(12):1219-25. PubMed ID: 1337163 [Abstract] [Full Text] [Related]
23. CAPD with low calcium dialysate and calcium carbonate: results of a 24-week study. Honkanen E, Kala AR, Grönhagen-Riska C, Ikäheimo R. Adv Perit Dial; 1992; 8():356-61. PubMed ID: 1361822 [Abstract] [Full Text] [Related]
25. A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis. Banalagay E, Bernardini J, Holley J, Chen T, Piraino B. Adv Perit Dial; 1993; 9():280-3. PubMed ID: 8105943 [Abstract] [Full Text] [Related]
26. Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations. Hutchison AJ, Were AJ, Boulton HF, Mawer EB, Laing I, Gokal R. Nephron; 1996; 72(1):52-8. PubMed ID: 8903861 [Abstract] [Full Text] [Related]
34. Differences in corrective mode for divalent ions and parathyroid hormone between standard- and low-calcium dialysate in patients on continuous ambulatory peritoneal dialysis--result of a nationwide survey in Japan. Yamamoto H, Kasai K, Hamada C, Hasegawa H, Higuchi C, Hiramatsu M, Hosoya T, Itami N, Kawanishi H, Kubota M, Masakane I, Minakuchi J, Mitarai T, Nakao T, Suzuki H, Tomo T, Kawaguchi Y, Japan Peritoneal Dialysis-Mineral Bone Disorders (PD-MBD) Research Group. Perit Dial Int; 2008 Jun; 28 Suppl 3():S128-30. PubMed ID: 18552242 [Abstract] [Full Text] [Related]
35. Effects of subcutaneous calcitriol administration on plasma calcium and parathyroid hormone concentrations in continuous ambulatory peritoneal dialysis uremic patients. Rolla D, Paoletti E, Marsano L, Mulas D, Peloso G, Cannella G. Perit Dial Int; 1993 Jun; 13(2):118-21. PubMed ID: 8494932 [Abstract] [Full Text] [Related]
36. [Dynamic changes in calcium and phosphate plasma concentrations in the patients on peritoneal dialysis]. Jovanović N, Lausević M, Stojimirović B. Vojnosanit Pregl; 2006 Jan; 63(1):27-30. PubMed ID: 16471245 [Abstract] [Full Text] [Related]
37. Reduced calcium dialysate in CAPD patients: efficacy and limitations. Armstrong A, Beer J, Noonan K, Cunningham J. Nephrol Dial Transplant; 1997 Jun; 12(6):1223-8. PubMed ID: 9198055 [Abstract] [Full Text] [Related]
38. Long-term effects on PTH and mineral metabolism of 1.25 versus 1.75 mmol/L dialysate calcium in peritoneal dialysis patients: a meta-analysis. Jin L, Zhou J, Shao F, Yang F. BMC Nephrol; 2019 Jun 11; 20(1):213. PubMed ID: 31185931 [Abstract] [Full Text] [Related]